SalvaRx Group PLC | Income Statement

Fiscal year is January-December. All values GBP Thousands.
2011
2012
2013
2014
2015
SG&A Expense
5,285.00
3,605.00
-
-
194.00
EBIT
5,285.00
3,605.00
-
-
194.00
Unusual Expense
-
2,077.00
-
-
-
Non Operating Income/Expense
2,747.00
520.00
-
-
-
Pretax Income
2,328.00
5,906.00
-
-
192.00
Income Tax
-
1.00
-
-
-
Equity in Affiliates
-
123.00
-
-
-
Consolidated Net Income
2,328.00
6,030.00
-
-
192.00
Net Income
2,328.00
6,030.00
-
-
192.00
Net Income After Extraordinaries
2,328.00
6,030.00
4,307.00
35,024.00
48.00
Net Income Available to Common
2,328.00
6,030.00
4,307.00
35,024.00
311.00
EPS (Basic)
3.00
7.00
5.00
41.00
0.07
Basic Shares Outstanding
696.60
847.80
848.00
851.60
4,921.90
EPS (Diluted)
3.34
7.11
5.08
41.13
0.07
Diluted Shares Outstanding
696.60
847.80
848.00
851.60
4,921.90
EBITDA
5,285.00
3,605.00
-
-
194.00
Non-Operating Interest Income
210.00
296.00
-
-
2.00

About SalvaRx Group

View Profile
Address
Commerce House
Ramsey Isle of Man IM8 2LQ
United Kingdom
Employees -
Website http://www.salvarx.io
Updated 07/08/2019
SalvaRx Group Plc is a drug discovery and development company which focuses on immune-oncology. It invests in novel cancer immune-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies. The company was founded by Ian B.